Leo R Brown, MD in Rupert, ID - Surgery

Leo R Brown, MD is a Surgery physician based in Rupert, Idaho. Leo R Brown is licensed to practice in Idaho (license number M3607) and his current practice location is 133 W 400 N, Rupert, Idaho. He can be reached at his office (for appointments etc.) via phone at (208) 436-0401.

NPI number for Leo R Brown is 1790809952 and his current mailing address is 133 W 400 N, Rupert, Idaho. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1790809952.

Contact Information

	Leo R Brown, MD
	133 W 400 N, Rupert, ID 83350-8547
	(208) 436-0401
	Not Available

Physician's Profile

Full Name	Leo R Brown
Gender	Male
Speciality	Surgery
Location	133 W 400 N, Rupert, Idaho
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1790809952
Provider Enumeration Date: 03/16/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Leo R Brown such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1790809952	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	M3607 (Idaho)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Leo R Brown is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Leo R Brown, MD 133 W 400 N, Rupert, ID 83350-8547 Ph: (208) 436-0401	Leo R Brown, MD 133 W 400 N, Rupert, ID 83350-8547 Ph: (208) 436-0401

News Archive

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

Resistance to CD19 CAR T-cell therapy can be caused by CD19 splicing alterations

Resistance to CD19 CAR T-cell therapy, a type of immunotherapy that yields long-lasting remissions in many patients with B-cell leukemia, can be caused by CD19 splicing alterations, leading to loss of certain parts of the CD19 protein that are recognized by the CAR T cells.

New blood test could help avoid more than 40% of prostate biopsies, study finds

A multi-center study that validates the clinical performance of IsoPSA - a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen - will be presented during a special press conference at the 13th Annual Meeting of the American Urological Association on May 18 in San Francisco.

Shannon installs Toshiba's Infinix CF-i single plane vascular X-ray system

Performing cardiac catheterizations through the radial artery is proven to lower the risk of vascular complications, reduce major bleeding and improve patient recovery time when compared to femoral access. Shannon Medical Center, in San Angelo, Texas, installed Toshiba America Medical Systems, Inc.'s Infinix CF-i single plane vascular X-ray system to conduct radial interventions more easily and improve patient safety and outcomes while reducing costs.

Study shows asthma mediator IL-13 prevents SARS-CoV-2 infection

In a paper published on the bioRxiv preprint server, researchers reported the results on whether IL-13 expression in asthma patients reduces their susceptibility to SARS-CoV-2 infection.

Leo R Brown, MD - Surgery in Rupert, ID